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Objectives: Evaluate the efficacy of adding two intravenous bolus of aminophylline to the
standard treatment of acute asthma episode in children admitted to the pediatric
emergency room (PER).
Methods: Between March 2001 and February 2002, 60 children (2–5 years old), admitted
to the PER at Hospital de Clı´nicas de Porto Alegre (Brazil), due to an episode of acute
asthma, refractory to conventional therapy (an oral dose of steroids and at least three
doses of inhaled albuterol, associated or not with oxygen) were enrolled in a randomized,
double blind, placebo controlled clinical trial. The randomization was performed in blocks
of 10 patients, who received a ‘‘bronchodilator solution’’ (either saline or aminophylline),
in two doses: on arrival at the PER and again 6 h later. The intervention group received
aminophylline 5mg/kg/dose diluted in normal saline (NS) solution up to a 20mL volume,
while the placebo group received plain NS, both in an infusion rate of 1 cc/min. The main
outcomes were total length of hospital stay, length of supplemental oxygen use, number
of bronchodilator nebulizations and/or aerosol inhalations performed and patient
destination. The groups were compared using the Students t-test, Mann–Whitney test
and Chi-Square test, accepting po0.05 as significant.
Results: Comparing the main outcomes, we did not find differences between the placebo
and aminophylline groups: 29.0714.7 versus 26.2713.4 beta-agonist nebulizations per
patient (p ¼ 0.46); 2.4710.6 versus 5.6714.2 aerosol inhalations per patient (p ¼ 0.32);
24.7730.0 versus 26.0725.2 h for oxygen supplement (p ¼ 0.86); 43.2730.0 versusElsevier Ltd. All rights reserved.
om FIPE (Fundo de Incentivo a Pesquisa e Eventos) of Hospital de Clı´nicas de Porto Alegre (Brazil).
ung, 101/72 Centro, Novo Hamburgo CEP-93510-340, RS, Brazil. Tel.: +55 51 5951014.
.br (R. Silveira D’A´vila), samantea@terra.com.br (S Luı´s Amantea).
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Intravenous aminophylline for acute asthma in children 15743.6723.7 h for length of hospital stay (p ¼ 0.95). We also did not find differences
between the two groups related to the blood pressure, heart rate, respiratory rate and
oxygen saturation.
Conclusion: In children aged 2–5 years admitted to a PER with asthma, two intravenous
doses of 5mg/kg of aminophylline given 6 h apart did not change the length of stay in
hospital, the number of nebulizations given or the duration of oxygen therapy required. We
are unable to tell whether there would be benefit with higher doses of aminophylline
designed to give levels in the usual therapeutic range.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Methylxanthines have been used for treating bronchial
asthma for over 50 years.1 Theophylline and the soluble
salt, aminophylline, have multiple potential beneficial
actions in asthma, e.g.: bronchial muscle relaxation,
improvement in diaphragm contractility, anti-inflammatory
effect, diuretic function and increase in mucociliary
activity.2
For a long time, aminophylline was considered as a first
line drug for the treatment of acute asthma. In the last 20
years, some studies failed for demonstrating any additional
benefit of this drug in the pediatric population, when
corticosteroids and beta-agonist therapy are properly used.
Nowadays aminophylline is considered as a second line drug
for acute asthma treatment.3–7
In spite of the above-mentioned studies, aminophylline is
still being considered as a therapeutic option in some
centers. Recently, aminophylline was considered by the UK
pediatricians working in the general wards as a first line
agent for emergency respiratory disease.8 We speculate that
in spite of the guidelines, there is no consensus among
pediatricians related to the aminophylline indications in
pediatric patients. It seems to be more significant for those
children with asthma attack under 5 years old.9
The aim of this study was to evaluate the efficacy of early
administration of two IV bolus of aminophylline added to
the conventional treatment in children (2–5 years old)
with acute asthma admitted to the pediatric emergency
room (PER).Patients and methods
Between March 2001 and February 2002, all 2–5 year old
children with a diagnosis of acute asthma admitted to the
PER at Hospital de Clı´nicas de Porto Alegre (HCPA) were
invited to participate in the study.
The inclusion criteria were the presence of an acute asthma
episode refractory to an oral dose of corticosteroids (pre-
dnisolone or prednisone 1mg/kg) and three consecutive
nebulizations with albuterol (150mg/kg/dose), or three con-
secutives inhalations of metered-dose albuterol (50mg/kg/
dose) over an 1-h period, associated or not with supplemental
oxygen (nasal catheter or mask) to maintain hemoglobin
saturation above 90%.
Patients who needed immediate tracheal intubation, had
known allergy to methylxanthines, had used such medica-
tion in the previous hours, had a history of difficult tocontrol convulsive seizures in the last week, had a seizure
episode at the time of admission, were excluded. To avoid
drug interactions, patients who were in current use of
erythromycin, cimetidine, phenytoin, phenobarbital, carba-
mazepine or rifampicin were also excluded.
The study was previously approved by the Committee of
Research and Ethics in Health at Hospital de Clı´nicas de
Porto Alegre (HCPA, Brazil). One of the parents of all
included children in the study should sign the informed
consent.
The diagnosis of refractory asthma and the indication for
admission to the pediatric emergency unit was exclusively
decided by discretion of the attending physicians. The
researchers had no influence on this decision neither on the
prescriptions.
The patients were allocated in two treatment groups.
Randomization was generated in blocks of 10 patients
(5 in each group). The intervention group (group I) received
two doses of IV aminophylline (5mg/kg—at 6 h of interval)
diluted in saline solution (up to 20 cc) and the placebo group
(group II) received two infusions (at 6 h of interval)
of normal saline (NS) solution (20 cc). The placebo solution
(NS solution) and aminophylline infusion had the same color
and volume (20mL) infused at a rate of 1 cc/h over 20min
and it was impossible to discriminate them by direct
inspection alone.
The head nurse of the PER was responsible for disclosing
the codes and preparing the solutions according to the
sequence of randomization. This nurse was not involved with
the patient care. The serum levels of aminophylline were
measured in 17% of patients from both groups. Thus, from
the 41st to the 50th patient, blood sample was collected 1 h
after the first dose of the solution infusion.
The attending physician in charge at the PER evaluated
clinically all patients included in the study. Clinical data
(heart rate, respiratory rate, hemoglobin oxygen saturation
and blood pressure) were recorded 15min before and after
the first dose and the second dose, and also 1, 12 and 24 h
after the second dose of the bronchodilator solution. The
patients were followed until the hospital discharge search-
ing for length of oxygen supply, number of inhaled albuterol,
length of hospital stay and internal transferences (ward or
PICU admission).
The protocol for initial asthma treatment at emergency
department is based on three inhaled doses of beta agonists
every 20min, systemic steroids and oxygen supply. Inhala-
tion with beta agonist could be delivered by: (a) nebuliza-
tion with face mask, at oxygen (8 L/min) and albuterol
(150 mg/kg till maximum of 5mg) diluted in NS (3mL);
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they were treated with MDI plus spacer (albuterol 50mg/kg up
to a maximum of 1000mg or 10 puffs). Inhaled albuterol at
every 20min is maintained over 1–4h depending on the
severity of the crisis and on the response of the patient. After
this period the interval could be enlarged (every hour) for
those patients who showed good response. For those children
not responding after 4 h of inhaled albuterol, intravenous
albuterol infusion or PICU admission is considered. The
researchers were not involved with these decisions that were
at the discretion of the staff members of the PER.
The main outcomes considered were length of supple-
mental oxygen, number of bronchodilator nebulizations or
aerosol puffs, length of stay in the PER (in h). The criteria
adopted by the staff members of the PER for defining
modifications in the treatment are based on: arterial
saturation of oxygen and signs of respiratory distress
(respiratory rate and retractions). Discharge was just
considered for those children without any respiratory
distress, on inhaled albuterol not more frequently than
every 3 h of interval and without oxygen supply. The staff
members defined the destination of the patient (hospital
discharge, transfer to the pediatric ward or to the ICU)
which was also considered as a main outcome.
To calculate the sample size, we defined a minimum
difference of 20% in the length of oxygen use (h), establish-
ing a ¼ 0.05 and b ¼ 0.10, to detect an effect size (mean/
standard deviation difference) greater than or equal to 0.90
(moderate magnitude). Taking these characteristics into
account and considering similar studies in medical litera-
ture, the estimated sample size was 30 patients per group.Table 1 General characteristics of the population.
Characteristics Aminophylline
Group I (n ¼ 3
Age (years)
Median (interquartile interval; 25–75%) 3.1 (2.4–3.8)
Male (%) 12 (40)
First episode of wheezing (months)
Median (interquartile interval; 25–75%) 12 (6.3–22.5)




Time of onset of current crisis (h)
Median (interquartile interval; 25–75%) 13.5 (8.3–18.8
Use of medication at home in the last 24 h (%)
Inhaled b-2 adrenergic 11 (36.7)
Oral b-2 adrenergic 3 (10)
Oral corticosteroids 8 (26.7)
Exposure to smoking at home: patients (%) 17 (56.7)
SD, standard deviation; EOR, emergency observation room; PICU, pe
*Student’s t-test for independent samples.
yMann–Whitney test.
zChi-Square test or Exact Fisher test.Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS 9.0 for windows, SPSS Inc.,
Chicago, IL, USA).
The continuous variables means were compared using the
Student’s t-test. For those variables without normal
distribution, Mann–Whitney test was used. Categorical
variables were compared through the Chi-Square test (using
the Yates correction), or the Exact Fisher test. We defined a
value of po0.05 as significant.Results
Between March 2001 and February 2002, 60 patients
were included in the study. There were no losses or
refusal by the family members. Although children in
both groups were more often enrolled during Autumn and
Winter (47/60; 78.3%), this difference was not significant
(p ¼ 0.34).
No significant differences were observed between the two
groups at the entry of the study in terms of general
characteristics (Table 1), except for the time after onset
of current attack at admission, which was shorter in the
aminophylline group (15.079.3 versus 22.0719.5 days;
p ¼ 0.04).
Half of the patients included in the study received at least
one nebulization before being admitted to the PER and
23.3% received an oral dose of steroids at home.
Physical examination findings at the time of study
enrollment were not different between the two treatment
groups (Table 2).Placebo
0) Group II (n ¼ 30) Total (n ¼ 60) p
2.9(2.4–4.4) 0.63y
9 (30) 21(35) 0.59z
12 (7.0–20.5) 0.85y
14 (46.7) 33 (55) 0.29z
17 (56.7) 28 (46.7) 0.19z
3 (10) 7 (11.7) 1.00z
) 17.5 (10–22.3) 0.43y
19 (63) 30 (50) 0.07z
3 (10) 6 (10) 1.00z
6 (20) 14 (23.3) 0.76z
17 (56.7) 34 (56.7) 1.00z
diatric intensive care unit.
ARTICLE IN PRESS
Table 2 Physical examination of the patients at the time of inclusion in the study.
Characteristics Aminophylline Placebo p
Group I (n ¼ 30) Group II (n ¼ 30)
Dyspnea
Absent 0 0 0.61
Moderate n (%) 29 (96.7) 27 (90)
Severe n (%) 1 (3.3) 3 (10)
Level of consciousness
Normal n (%) 28 (93.3) 22 (73.3)
Normal-excited n (%) 2 (6.7) 8 (26.7) 0.83
Excited-depressed 0 0
Use of accessory muscles
Mild 0 0
Moderate n (%) 26 (86.7) 26 (86.7) 1.00
Severe n (%) 4 (13.3) 4 (13.3)
Auscultation of the lungs
Wheezing at the end of expiration n (%) 2 (6.7) 4 (13.3)
Ins/expiratory wheezing n (%) 27 (90) 22 (73.4) 0.22
Inaudible vesicular murmur n (%) 1 (3.3) 4 (13.3)
Table 3 Interventions and outcomes observed in the aminophylline and placebo groups.
Characteristics Aminophylline Placebo p
Group I (n ¼ 30) Group II (n ¼ 30)
Number of nebulizations, per patient 24.5 (19–36) 23.0 (16–36) 0.46y
Number of sprays, per patient 30 (14–57) 28 (14–53) 0.64z
Length of oxygen use during the period in hospital (h) 17.5 (6–26) 19.4 (12–31) 0.39z
Length of hospital stay (h) 30.8 (24–55) 40.0 (26–55) 0.48z
Intravenous salbutamol n (%) 1 (3.3) 3 (10) 0.61y
Destination
Discharged from EOR n (%) 25 (83.3) 21 (70)
Admission to ward n (%) 5 (16.7) 8 (26.7) 0.36y
Admission to PICU n (%) 0 1 (3.3)
Median (interquartile interval; 25–75%).
yStudent’s t-test for independent samples.
zMann–Whitney test.
yChi-Square test or Exact Fisher test.
Intravenous aminophylline for acute asthma in children 159The mean serum level of aminophylline in the interven-
tion group was 7.3771.39 mg/mL, whereas in the placebo
group was 0.3870.11 mg/cc (po0.01).
No significant differences were found between the groups
related to the main outcomes (Table 3). Concerning to
supplemental oxygen, we observed that 5 patients (16.7%) in
group II did not use it, 12 (40%) needed it for at least 24 h by
extra nasal catheter and four (13.3%) for longer than 48 h.
On the other hand, in the intervention group seven (23.3%)
did not need it, 14(46.7%) used it for a period of at least 24 h
and 4 (13.3%) used it for a period of over 48 h, without any
significant difference in any of these parameters.
We did not find any statistical difference between both
groups related to the physiologic signs (Table 4) evaluated inthe ‘‘pre’’, ‘‘post’’ and ‘‘1 h later’’ moments for the IV bolus
infusions (groups I and II).Discussion
In this study we could not demonstrate any beneficial effect
when two IV loading doses of aminophylline were added to
the standard treatment for acute asthma in children less
than 5 years old admitted to the emergency department in
consequence of refractory crisis. We did not observe any
significant difference between the two groups related to the
length of stay in the observation room, the length of oxygen
use, the number of beta agonist nebulizations and/or the
ARTICLE IN PRESS
Table 4 Physiologic variables of patients with acute severe asthma pre, post and 1 h after IV bolus infusions.
Variables Aminophylline Placebo p
Group I (n ¼ 30) Group II (n ¼ 30)
Heart rate
Pre 146.47712.29 145.40716.26 0.78
Post 146.43715.10 140.27716.89 0.14
1 h after 141.03717.46 142.57718.95 0.75
Respiratory rate
Pre 46.1779.84 42.80710.37 0.20
Post 45.2378.26 42.90711.05 0.36
1 h after 43.3778.83 41.0378.51 0.30
Systolic blood pressure
Pre 105.17714.88 107.33717.21 0.30
Post 110.67721.16 106.33714.97 0.18
1 h after 106.00719.40 106.67716.47 0.44
Diastolic blood pressure
Pre 64.00710.03 62.8378.87 0.32
Post 66.00714.29 62.5079.17 0.13
1 h after 63.67711.59 62.6779.07 0.35
Hemoglobin saturation
Pre 94.3071.86 94.6073.11 0.65
Post 95.3371.79 95.5371.70 0.66
1 h after 95.2772.32 95.4772.29 0.74
Data presented as mean7standard deviation. HR, heart rate; RR, respiratory rate; BP, blood pressure; Hb, hemoglobin. Pre ¼ 15min
before IV bolus infusion; post ¼ 15min after IV bolus infusion
R. Silveira D’A´vila et al.160MDI puffs administered the destination of these patients
(admission to the ward or to the PICU and/or discharge from
PER). These findings are in accordance with other previous
studies enrolling older children.10–12
Some systematic reviews evaluating the use of aminophyl-
line compared to placebo in children with acute asthma
attack, demonstrated an improvement in lung function tests
in the intervention group.13 However, as in our study, the
length of hospital stay and the number of nebulizations
performed with beta agonists were not reduced.13 On the
other hand, there are few studies that were able for
demonstrating better outcomes when aminophylline was
added to the standard treatment in children with acute
asthma.14–16
These intriguing and controversial results involving
aminophylline in children with acute asthma could be
explained by different criteria inclusion and/or methodolo-
gical aspects.
In spite of these controversy results related to aminophyl-
line in asthma, this drug is still used at some centers.8
Recently, it was demonstrated that aminophylline was
available in over 90% of the general pediatrician’s wards in
United Kingdom. The pediatric staff working in these units
elected aminophylline as one of the six most useful drugs for
caring children in emergency situations.8 This position is in
opposition to the current opinion and international guide-
lines for asthma treatment in children.3,6
Conversely, Kelly, evaluating 38 emergency departments
in Australia, observed that aminophylline was administered
just to 6 of 1340 acute asthma crisis.17 It should be remarked
that five of these six patients had severe asthma attack.
Based on our results and on other studies it seems reason-able that children with acute mild to moderate asthma have
no benefits in adding aminophylline to the standard
treatment. It could be reserved for those children candi-
dates to PICU admission and/or submitted to the mechanical
ventilation, where some benefits could be expected with
this drug.15,18
Until this moment there were few studies evaluating the
effect of IV bolus of aminophylline in children with acute
asthma less than 5 years old. Our results demonstrated that
these young group has the same response that is observed in
older children when receiving the drug in a constant
infusion.11,14,15
This study may have some bias. Our definition for
refractory acute asthma attack was based only on the lack
of response to the initial treatment, without an objective
quantification. Nevertheless, this is an intrinsic restriction
related to the age of the study subjects. The adopted
criteria (lack of response to three consecutive nebulizations
associated to a systemic steroid and the need of admission
to the PER) reflect the real scenario at the most of pediatric
emergency department, which is based on clinical response.
As observed in an studies 15,19 the majority of our patients
would be classified as having mild to moderate acute asthma
(see Table 2). In spite of being young children, this group
with less severe asthma crisis demonstrated the same
response observed in older children to the beta-agonist
treatment.
For obtaining the maximal bronchodilator effect an
aminophylline serum level between 10 and 20 mg/mL is
recommended. However, considering the risk for side effects
some authors have proposed aminophylline serum levels
between 5 and 15mg/L which could have an acceptable
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average serum level of aminophylline (7.3771.39mg/mL)
measured 1 h after the first IB bolus infusion in 17% of the
intervention group was included in this range.
However, the aim of our study was not to obtain a
dose–response curve for aminophylline infusion. We in-
tended to evaluate the effect of two IV loading doses of
aminophylline added to the conventional treatment for
acute asthma in children. For acute refractory asthma
attack, aminophylline or beta2-agonist could be adminis-
tered in a continuous infusion after a loading dose.3,6
Nevertheless some studies have demonstrated that an early
IV loading dose of salbutamol added to the conventional
treatment for acute asthma in children admitted to the
emergency room was able to decrease the length of stay, the
number of nebulizations and the length of oxygen sup-
ply.21,22 We speculate that in such peculiar group the same
effect could be achieved after two bolus of aminophylline
infusion. Two intravenous doses of 5mg/kg of aminophylline
given 6 h apart did not demonstrate any benefit when added
to the conventional treatment for acute asthma in children
aged 2–5 years admitted to a PER. We are unable to tell
whether there would be benefit with higher doses of
aminophylline designed to give levels in the usual ther-
apeutic range.
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